BACKGROUND Coronary heart disease(CHD)and heart failure(HF)are the major causes of morbidity and mortality worldwide.Early and accurate diagnoses of CHD and HF are essential for optimal management and prognosis.Howeve...BACKGROUND Coronary heart disease(CHD)and heart failure(HF)are the major causes of morbidity and mortality worldwide.Early and accurate diagnoses of CHD and HF are essential for optimal management and prognosis.However,conventional diagnostic methods such as electrocardiography,echocardiography,and cardiac biomarkers have certain limitations,such as low sensitivity,specificity,availability,and cost-effectiveness.Therefore,there is a need for simple,noninvasive,and reliable biomarkers to diagnose CHD and HF.AIM To investigate serum cystatin C(Cys-C),monocyte/high-density lipoprotein cholesterol ratio(MHR),and uric acid(UA)diagnostic values for CHD and HF.METHODS We enrolled 80 patients with suspected CHD or HF who were admitted to our hospital between July 2022 and July 2023.The patients were divided into CHD(n=20),HF(n=20),CHD+HF(n=20),and control groups(n=20).The serum levels of Cys-C,MHR,and UA were measured using immunonephelometry and an enzymatic method,respectively,and the diagnostic values for CHD and HF were evaluated using receiver operating characteristic(ROC)curve analysis.RESULTS Serum levels of Cys-C,MHR,and UA were significantly higher in the CHD,HF,and CHD+HF groups than those in the control group.The serum levels of Cys-C,MHR,and UA were significantly higher in the CHD+HF group than those in the CHD or HF group.The ROC curve analysis showed that serum Cys-C,MHR,and UA had good diagnostic performance for CHD and HF,with areas under the curve ranging from 0.78 to 0.93.The optimal cutoff values of serum Cys-C,MHR,and UA for diagnosing CHD,HF,and CHD+HF were 1.2 mg/L,0.9×10^(9),and 389μmol/L;1.4 mg/L,1.0×10^(9),and 449μmol/L;and 1.6 mg/L,1.1×10^(9),and 508μmol/L,respectively.CONCLUSION Serum Cys-C,MHR,and UA are useful biomarkers for diagnosing CHD and HF,and CHD+HF.These can provide information for decision-making and risk stratification in patients with CHD and HF.展开更多
目的探究栀子豉汤联合阿米替林对心肌梗死后抑郁患者血清胱抑素C(cystatin C,CysC)水平、血小板与淋巴细胞比值(platelet to lymphocyte ratio,PLR)的影响。方法选取2022年6月—2023年4月收治的63例心肌梗死后抑郁患者作为研究对象。根...目的探究栀子豉汤联合阿米替林对心肌梗死后抑郁患者血清胱抑素C(cystatin C,CysC)水平、血小板与淋巴细胞比值(platelet to lymphocyte ratio,PLR)的影响。方法选取2022年6月—2023年4月收治的63例心肌梗死后抑郁患者作为研究对象。根据治疗方法不同分为联合组(32例,栀子豉汤联合阿米替林治疗)和对照组(31例,阿米替林治疗),治疗4周后,观察两组临床疗效、中医证候积分、CysC、PLR、5-羟色胺(5-hydroxytryptamine,5-HT)、脑源性神经营养因子(brain-derived neurotrophic factor,BDNF)、汉密尔顿抑郁量表、心率变异性指标、不良反应。结果联合组总有效率96.88%(31/32)高于对照组80.65%(25/31)(P<0.05)。联合组情志不畅、烦躁、兴趣索然、失眠得分低于对照组(P<0.05)。联合组CysC、PLR低于对照组(P<0.05)。联合组5-HT、BDNF高于对照组(P<0.05)。联合组汉密尔顿抑郁量表评分少于对照组(P<0.05)。联合组连续24 h内正常RR间期均值标准差(standard deviation of all normal to normal RR intervals,SDNN)、每5 min窦性RR间期均值标准差(standard deviation of 5-min mean RR intervals,SDANN)、相邻正常RR间期差值均方根(root-mean square of difference of successive RR intervals,rMSSD)高于对照组(P<0.05)。两组不良反应比较差异无统计学意义(P>0.05)。结论栀子豉汤联合阿米替林治疗心肌梗死后抑郁患者效果明显,能明显改善临床症状,降低血清CysC水平及PLR,改善5-HT和BDNF,提升心脏功能,且不会增加不良反应。展开更多
目的探究利拉鲁肽与西格列汀对早期2型糖尿病肾病(T2DN)患者肾脏血流动力学及中性粒细胞/淋巴细胞比值(NLR)、血清胱抑素C(CysC)、单核细胞趋化因子-1(MCP-1)的影响。方法选取2020年12月—2022年12月邯郸市第一医院内分泌一科收治的早期...目的探究利拉鲁肽与西格列汀对早期2型糖尿病肾病(T2DN)患者肾脏血流动力学及中性粒细胞/淋巴细胞比值(NLR)、血清胱抑素C(CysC)、单核细胞趋化因子-1(MCP-1)的影响。方法选取2020年12月—2022年12月邯郸市第一医院内分泌一科收治的早期T2DN患者110例为研究对象。按随机数排秩法将患者分为对照组(n=55)与观察组(n=55)。对照组予以西格列汀治疗,观察组予以利拉鲁肽联合西格列汀治疗,2组患者均治疗12周。比较2组疗效、血糖指标、双肾主动脉(MRA)和叶间动脉(IRA)的肾脏血流动力学指标、NLR、Cys-C、MCP-1以及不良反应发生情况,分析尿蛋白排泄率(UAER)与血清NLR、CysC、MCP-1的关系。结果观察组总有效率为90.91%,高于对照组的67.27%(χ^(2)/P=9.290/0.002)。治疗12周后,2组HbA_(1c)、FPG、2 h PG水平较治疗前降低,且观察组低于对照组(t/P=4.222/<0.001、6.064/<0.001、6.648/<0.001);2组IRA、MRA的Vdmin、Vsmax较治疗前升高,且观察组较对照组升高更明显(t/P=3.733/<0.001、6.800/<0.001,2.598/0.011、2.043/0.043);2组IRA、MRA的PI、RI较治疗前降低,且观察组较对照组降低更明显(t/P=4.194/<0.001、3.933/<0.001,3.265/0.001、6.171/<0.001);2组UAER、NLR、Cys-C、MCP-1水平较治疗前明显降低,且观察组较对照组降低更明显(t/P=14.534/<0.001、2.609/0.010、9.795/<0.001、6.618/<0.001);Pearson分析,NLR、Cys-C、MCP-1与UAER均呈正相关(r=0.513、0.764、0.685,P均<0.001)。2组不良反应发生率比较差异无统计学意义(χ^(2)/P=0.910/0.340)。结论利拉鲁肽联合西格列汀治疗早期T2DN具有良好疗效,可有效改善肾脏血流动力学,调节NLR、Cys-C、MCP-1水平,保护肾功能。展开更多
文摘BACKGROUND Coronary heart disease(CHD)and heart failure(HF)are the major causes of morbidity and mortality worldwide.Early and accurate diagnoses of CHD and HF are essential for optimal management and prognosis.However,conventional diagnostic methods such as electrocardiography,echocardiography,and cardiac biomarkers have certain limitations,such as low sensitivity,specificity,availability,and cost-effectiveness.Therefore,there is a need for simple,noninvasive,and reliable biomarkers to diagnose CHD and HF.AIM To investigate serum cystatin C(Cys-C),monocyte/high-density lipoprotein cholesterol ratio(MHR),and uric acid(UA)diagnostic values for CHD and HF.METHODS We enrolled 80 patients with suspected CHD or HF who were admitted to our hospital between July 2022 and July 2023.The patients were divided into CHD(n=20),HF(n=20),CHD+HF(n=20),and control groups(n=20).The serum levels of Cys-C,MHR,and UA were measured using immunonephelometry and an enzymatic method,respectively,and the diagnostic values for CHD and HF were evaluated using receiver operating characteristic(ROC)curve analysis.RESULTS Serum levels of Cys-C,MHR,and UA were significantly higher in the CHD,HF,and CHD+HF groups than those in the control group.The serum levels of Cys-C,MHR,and UA were significantly higher in the CHD+HF group than those in the CHD or HF group.The ROC curve analysis showed that serum Cys-C,MHR,and UA had good diagnostic performance for CHD and HF,with areas under the curve ranging from 0.78 to 0.93.The optimal cutoff values of serum Cys-C,MHR,and UA for diagnosing CHD,HF,and CHD+HF were 1.2 mg/L,0.9×10^(9),and 389μmol/L;1.4 mg/L,1.0×10^(9),and 449μmol/L;and 1.6 mg/L,1.1×10^(9),and 508μmol/L,respectively.CONCLUSION Serum Cys-C,MHR,and UA are useful biomarkers for diagnosing CHD and HF,and CHD+HF.These can provide information for decision-making and risk stratification in patients with CHD and HF.
文摘目的探究栀子豉汤联合阿米替林对心肌梗死后抑郁患者血清胱抑素C(cystatin C,CysC)水平、血小板与淋巴细胞比值(platelet to lymphocyte ratio,PLR)的影响。方法选取2022年6月—2023年4月收治的63例心肌梗死后抑郁患者作为研究对象。根据治疗方法不同分为联合组(32例,栀子豉汤联合阿米替林治疗)和对照组(31例,阿米替林治疗),治疗4周后,观察两组临床疗效、中医证候积分、CysC、PLR、5-羟色胺(5-hydroxytryptamine,5-HT)、脑源性神经营养因子(brain-derived neurotrophic factor,BDNF)、汉密尔顿抑郁量表、心率变异性指标、不良反应。结果联合组总有效率96.88%(31/32)高于对照组80.65%(25/31)(P<0.05)。联合组情志不畅、烦躁、兴趣索然、失眠得分低于对照组(P<0.05)。联合组CysC、PLR低于对照组(P<0.05)。联合组5-HT、BDNF高于对照组(P<0.05)。联合组汉密尔顿抑郁量表评分少于对照组(P<0.05)。联合组连续24 h内正常RR间期均值标准差(standard deviation of all normal to normal RR intervals,SDNN)、每5 min窦性RR间期均值标准差(standard deviation of 5-min mean RR intervals,SDANN)、相邻正常RR间期差值均方根(root-mean square of difference of successive RR intervals,rMSSD)高于对照组(P<0.05)。两组不良反应比较差异无统计学意义(P>0.05)。结论栀子豉汤联合阿米替林治疗心肌梗死后抑郁患者效果明显,能明显改善临床症状,降低血清CysC水平及PLR,改善5-HT和BDNF,提升心脏功能,且不会增加不良反应。
文摘目的探究利拉鲁肽与西格列汀对早期2型糖尿病肾病(T2DN)患者肾脏血流动力学及中性粒细胞/淋巴细胞比值(NLR)、血清胱抑素C(CysC)、单核细胞趋化因子-1(MCP-1)的影响。方法选取2020年12月—2022年12月邯郸市第一医院内分泌一科收治的早期T2DN患者110例为研究对象。按随机数排秩法将患者分为对照组(n=55)与观察组(n=55)。对照组予以西格列汀治疗,观察组予以利拉鲁肽联合西格列汀治疗,2组患者均治疗12周。比较2组疗效、血糖指标、双肾主动脉(MRA)和叶间动脉(IRA)的肾脏血流动力学指标、NLR、Cys-C、MCP-1以及不良反应发生情况,分析尿蛋白排泄率(UAER)与血清NLR、CysC、MCP-1的关系。结果观察组总有效率为90.91%,高于对照组的67.27%(χ^(2)/P=9.290/0.002)。治疗12周后,2组HbA_(1c)、FPG、2 h PG水平较治疗前降低,且观察组低于对照组(t/P=4.222/<0.001、6.064/<0.001、6.648/<0.001);2组IRA、MRA的Vdmin、Vsmax较治疗前升高,且观察组较对照组升高更明显(t/P=3.733/<0.001、6.800/<0.001,2.598/0.011、2.043/0.043);2组IRA、MRA的PI、RI较治疗前降低,且观察组较对照组降低更明显(t/P=4.194/<0.001、3.933/<0.001,3.265/0.001、6.171/<0.001);2组UAER、NLR、Cys-C、MCP-1水平较治疗前明显降低,且观察组较对照组降低更明显(t/P=14.534/<0.001、2.609/0.010、9.795/<0.001、6.618/<0.001);Pearson分析,NLR、Cys-C、MCP-1与UAER均呈正相关(r=0.513、0.764、0.685,P均<0.001)。2组不良反应发生率比较差异无统计学意义(χ^(2)/P=0.910/0.340)。结论利拉鲁肽联合西格列汀治疗早期T2DN具有良好疗效,可有效改善肾脏血流动力学,调节NLR、Cys-C、MCP-1水平,保护肾功能。
